Lung Cancer

When added to treatment with docetaxel, the investigational drug plinabulin improved overall survival by 4.7 months in patients with advanced non–small-cell lung cancer with measurable lesions.
Targeted agents and immunotherapy are displacing chemotherapy in certain subgroups of the treatment of lung cancer, but chemotherapy remains a key therapeutic pillar in the daily management of patients with this disease, according to Jean-Charles Soria, MD, PhD, Head of the Drug Development Department, Gustave Roussy, Villejuif, France.
The first liquid biopsy used to detect gene mutations that are associated with non–small-cell lung cancer (NSCLC) was approved by the US Food and Drug Administration (FDA).
Boston, MA–In a first-of-its-kind study, aprepitant (Emend), a centrally acting neurokinin (NK)-1 antagonist indicated for the treatment of chemotherapy-induced nausea and vomiting (CINV), led to a reduction in cough frequency and an improvement in the objective and subjective measures of cough in patients with lung cancer.
Boston, MA-What is the best chemotherapy regimen to use for patients with locally advanced nonsquamous non-small-cell lung cancer (NSCLC)? The phase 3 PROCLAIM trial attempted to answer this question, but the study failed to determine the best regimen for this patient population.
What is the best chemotherapy regimen to use for patients with locally advanced nonsquamous non–small-cell lung cancer (NSCLC)? The phase 3 PROCLAIM trial attempted to answer this question, but the study failed to determine the best regimen for this patient population.
“There’s a lot we don’t know about lung cancer screening,” according to Denise Aberle, MD, who spoke at the recent American Association for Cancer Research International Conference on Frontiers in Cancer Prevention Research.
For the first time, a therapy for non-small cell lung cancer (NSCLC) has achieved more responses in smokers than nonsmokers. The antibody MPDL3280A also achieved good responses in the squamous and adenoma histologic types of NSCLC.
In the ongoing phase 3 PROFILE 1007 study of patients with previously treated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer, crizotinib improved quality of life (QOL) and key lung cancer symptoms compared with chemotherapy.
In a phase 3 head-to-head comparison trial, the anaplastic lymphoma kinase (ALK) inhibitor crizotinib proved more effective than standard chemo­therapy with pemetrexed or doce­taxel as a second-line treatment for non–small cell lung cancer (NSCLC) patients with the ALK genetic abnormality.
Page 10 of 11
Results 91 - 100 of 109